Goldman Sachs moved to Not Rated on Fulcrum Therapeutics and removed the firm’s 12-month price target on the shares, consistent with the practice for early-stage biotech companies under the firm’s coverage, after Fulcrum announced that the Phase 3 REACH study of losmapimod failed to demonstrate a statistically significant improvement on the primary endpoint of reachable workspace, or RWS. Following these results, the company said it will continue to advance pociredir in sickle cell disease, or SCD, and its preclinical Diamond-Blackfan Anemia, or DBA, program, the firm noted.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Moderna, Halliburton downgraded: Wall Street’s top analyst calls
- Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Fulcrum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- Leerink gives Fulcrum fourth downgrade after study failure